Telcyta

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2013
02420042013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Canfosfamide (TLK286, TELCYTA) is a prodrug that upon activation by glutathione transferase P1-1 (GST P1-1) yields an anticancer… (More)
Is this relevant?
2009
2009
RATIONALE Canfosfamide HCl (CAN) is a glutathione analogue prodrug that is activated by glutathione S-transferase P1-1 and… (More)
Is this relevant?
Review
2008
Review
2008
Ovarian cancer, although a chemo-sensitive disease, is associated with high morbidity and mortality due to its often-late… (More)
Is this relevant?
Review
2006
Review
2006
Nitric oxide (NO) is an endogenous, diffusible, transcellular messenger shown to affect regulatory and signaling pathways with… (More)
  • figure 2
  • figure 1
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2005
2005
The purpose of this study was to determine the safety and efficacy of TLK286 (TELCYTA(TM)), a glutathione analog prodrug, in… (More)
Is this relevant?
2004
2004
PURPOSE To determine the dose-limiting toxicities, maximum tolerated dose, and pharmacokinetics of TLK286, a novel cancer prodrug… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2004
2004
5060 Background: TLK286 (Telcyta) is a novel glutathione analog prodrug activated by GST P1-1, which is overexpressed in ovarian… (More)
Is this relevant?
Review
2004
Review
2004
  • Drugs in R&D
  • 2004
TLK 286 [TELCYTA] is an antitumour agent in clinical development with Telik. It was developed through the application of Telik's… (More)
Is this relevant?
2004
2004
7140 Background: TLK286 (Telcyta) is a novel glutathione analog prodrug activated by GST P1-1, which is overexpressed in NSCLC… (More)
Is this relevant?
2004
2004
5062 Background: TLK286 (Telcyta) is a glutathione analog prodrug activated by GST P1-1, which is overexpressed in ovarian cancer… (More)
Is this relevant?